BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - BIOA
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
BioAge Labs Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ:BIOA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
BIOA ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of BioAge Labs, Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Bronstein, Gewirtz & Grossman, LLC Encourages BioAge Labs, Inc. (BIOA) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioAge Labs, Inc. ("BioAge Labs" or "the Company") (NASDAQ:BIOA). Investors who purchased BioAge Labs securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIOA.
BioAge Labs, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by BioAge Labs, Inc. (BIOA)
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of BioAge Labs, Inc. ("BioAge Labs, Inc.") (NASDAQ:BIOA) concerning possible violations of federal securities laws. After the company discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns over elevated liver transaminase levels in participants.
Crude Oil Gains 2%; BioAge Labs Shares Plunge
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday.
BioAge Labs, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation
BOSTON, MA / ACCESSWIRE / December 9, 2024 / Block & Leviton is investigating BioAge Labs, Inc. (Nasdaq:BIOA) for potential securities law violations. Investors who have lost money in their BioAge Labs, Inc. investment should contact the firm to learn more about how they might recover those losses.
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Monday.
BioAge discontinues mid-stage trial of obesity drug
BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
One of these businesses is a risky play, but the other is very likely to succeed.
